October 25, 2017 06:08 PM EDTUpdated 07:27 PM
R&D

Am­gen buries the last big CETP drug, mark­ing the bit­ter end of a block­buster quest

John Carroll

Editor & Founder

Am­gen used its Q3 re­port to­day to quick­ly bury the last broad­ly fo­cused CETP drug in the clin­ic, clos­ing the fi­nal chap­ter in an R …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

Trump pledges his sup­port for a change to the IRA long sought by drug­mak­ers

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times